The potential of Bruton’s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease

BTK inhibitors represent a promising therapeutic avenue for immune-mediated dermatological conditions, offering oral administration, targeted pathway inhibition, and a favorable safety profile compared to biologic therapies. Ongoing research and clinical trials hold the potential to address unmet needs and reshape the therapeutic landscape in dermatology.